Grail Stock Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
AI Image

Grail Stock Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

Investor's Business Daily business

Key Points:

  • Investor’s Business Daily provides information solely for informational and educational purposes and does not offer investment advice or recommendations.
  • The data presented is sourced from what is believed to be reliable providers, but accuracy, timeliness, and suitability are not guaranteed.
  • Past investment performance is not indicative of future results, and authors may hold positions in the stocks they discuss.
  • Real-time pricing is provided by Nasdaq Last Sale, with ownership and estimate data from LSEG and FactSet, but not all markets are covered.
  • The content and trademarks are the property of Investor’s Business Daily, LLC, and information is subject to change without prior notice.

Trending Business

Trending Technology

Trending Health